Are saudi doctors following safety rules for a common arthritis drug?
NCT ID NCT06714461
First seen Apr 07, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study looks at whether healthcare professionals in Saudi Arabia are aware of and follow safety measures for the drug Leflunomide (ARAVA), used for rheumatoid and psoriatic arthritis. Researchers will survey about 3,500 doctors and pharmacists to see if they received and read safety materials, and if they counsel patients and order lab tests as recommended. The goal is to improve safe use of the medication, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sanofi-Aventis
Chilly-Mazarin, 91380, France
Conditions
Explore the condition pages connected to this study.